Bibliographic details
Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. Journal of Medical Economics 2009; 12(4): 291-300
MeSH
Antibodies, Monoclonal /administration & Antibodies, Monoclonal, Humanized; Antiviral Agents /administration & Bronchopulmonary Dysplasia /drug therapy /economics /virology; Clinical Trials as Topic; Cost-Benefit Analysis; Heart Defects, Congenital /drug therapy /economics /virology; Humans; Infant; Infant, Newborn; Infant, Premature; Netherlands; Palivizumab; Quality-Adjusted Life Years; Respiratory Syncytial Virus Infections /drug therapy /economics /prevention & Risk Factors; control; dosage /economics; dosage /economics